We are live on ! Find out more
FMS icon

Fresenius Medical Care

22.86 USD
+0.51
2.28%
At close Updated Sep 14, 4:00 PM EDT
Pre-market
After hours
22.23
-0.63
2.76%
1 day
2.28%
5 days
0.44%
1 month
-3.83%
3 months
-2.52%
6 months
-0.65%
Year to date
-2.76%
1 year
-7.49%
5 years
-37.28%
10 years
-48.03%
 

About: Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.

Employees: 108,165

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 50%
Neutral 31.3%
Negative 18.8%
Neutral
Zacks Investment Research
11 days ago
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.
Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?
Positive
Zacks Investment Research
11 days ago
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Fresenius Medical's improving profitability, 5008X rollout and value-based care gains offer support despite volume and reimbursement risks.
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
Positive
Morningstar
26 days ago
3 Cheap International Stocks to Buy
These stocks have economic moats and look attractive today.
3 Cheap International Stocks to Buy
Neutral
Zacks Investment Research
1 month ago
FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand
FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.
FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand
Neutral
Seeking Alpha
1 month ago
Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript
Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript
Fresenius Medical Care AG (FMS) Q2 2026 Earnings Call Transcript
Negative
MarketBeat
1 month ago
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
Fresenius Medical Care AG & Co. KGaA NYSE: FMS reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year outlook despite weaker U.S. treatment volumes and anticipated reimbursement-related headwinds in the second half.
Fresenius Medical Care AG & Co. KGaA Q2 Earnings Call Highlights
Negative
WSJ
1 month ago
Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further
Shares fell, wiping out most of their gains since the start of the year, after the German dialysis specialist reported another decline in U.S. treatment volumes in the second quarter.
Fresenius Medical Care Shares Drop After U.S. Treatment Volumes Fall Further
Negative
Reuters
1 month ago
Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again
Fresenius Medical Care shares fell in early trade on Tuesday, as investors looked past a second-quarter profit beat to ​focus on a fresh disappointment in U.S. patient volumes ‌and the management's decision to merely confirm, not raise, the full-year guidance.
Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again
Positive
Reuters
1 month ago
Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook
Fresenius Medical Care on Monday reported second-quarter operating income well ahead of ​market expectations and reaffirmed its full-year outlook, ‌as its cost-cutting programme and favourable U.S. reimbursement rates offset a deepening decline in patient ​treatment volumes.
Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook
Positive
Proactive Investors
1 month ago
Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to impose a 100% tariff on imported generic medicines from August 2028, rising to 200% a year later.
Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi
Price charts implemented using Lightweight Charts™